Page 69 - MemoriaEHD-Eng

www.ciberehd.org

• C a, B x, Q e, B L, C J, s D. Risk of advanced proxi-
Most relevant asteLLsessauiNterouJaNDauBieLLaaLas
mal neoplasms according to distal colorectal findings: comparison of sigmoidoscopy-
scientific based strategies.J Natl Cancer Inst. 2013 Jun 19;105(12):878-86.

articles
• vaN Der pas Mh, hagLiND e, Cuesta Ma, Fürst a, LaCy aM, hop WC. Laparoscopic versus
open surgery for rectal cancer (COLOR II): short-term outcomes of a randomised,

phase 3 trial.Lancet Oncol. 2013 Mar;14(3):210-8.

• CasteLLs a, giarDieLLo FM. Familial colorectal cancer screening: so close, so far.Gas-
troenterology. 2013 Mar;144(3):492-4.

• g M, C C, F a, C D, i JL, r-C J. Reg3β defi-
iroNeLLaaLvoerNáNDezLosaovaNNaoseLLoataFau
ciency impairs pancreatic tumor growth by skewing macrophage polarization.Cancer
Res. 2013 Sep 15;73(18):5682-94.

The research areas of our group are aimed at investigating the mechanisms in-
Highlights
volved in the development and progression of gastrointestinal and pancreatic pre-

malignant and malignant lesions, in order to establish new diagnostic, therapeutic
and/or preventive strategies. The main achievements in 2013 are those obtained

in the context of cooperative projects lead by our group in the fields of colorectal
cancer (CRC) screening and development of biomarkers for its early detection.

With respect to CRC screening, it is important to mention the ColonPrev project,

a prospective, randomized controlled trial comparing fecal immunochemical test-

ing and colonoscopy. After presenting the results of the first round (N Engl J Med
2012;366:697-706), we have recently published those corresponding to nested

projects, including the evaluation of sigmoidoscopy as screening strategy (J Natl

Cancer Inst 2013;105:878-86), the identification of factors influencing the ade-
noma detection rate (Gastrointest Endosc 2013;77:381-9), and the establishment

of serrated lesions as risk factor for advanced neoplasia (Gastrointest Endosc
2013;78:333-41).

The development and validation of biomarkers for early diagnosis of CRC, in the

context of the EPICOLON project, constitute a cross-sectional strategic action of

various CIBEREHD groups. In this field, it is worth to highlight recent publications
(Clin Gastroenterol Hepatol 2013;11:681-8; Gastroenterology 2013;144:926-

32; Clin Gastroenterol Hepatol 2013;11:705-11), patents (PCT/US2013/028401,

US61/391585 and US61/550148), and the grant from the Spanish Association
against Cancer obtained by our group.

Finally, the social commitment of our group has been demonstrated by the sup-

port to the creation of the Association of Families Affected by Lynch Syndrome
(www.afalynch.org) and the foundation of the Spanish Alliance for Colon Cancer

Prevention (www.alianzaprevencioncolon.es).

13
20
T
OR
P
RE
L
A
NU
N
A
D /
H
E
ER
IB
C

69